Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1ß inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.

Ridker, Paul M; MacFadyen, Jean G; Thuren, Tom; Libby, Peter

Ridker, Paul M; MacFadyen, Jean G; Thuren, Tom; Libby, Peter.

Afiliación

Ridker PM; Department of Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02215, USA.
MacFadyen JG; Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Thuren T; Department of Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02215, USA.
Libby P; Novartis Pharmaceutical Corporation, One Health Plaza, East Hanover, NJ 07936, USA.

Eur Heart J ; 41(23): 2153-2163, 2020 06 14.

Article en En | MEDLINE | ID: mdl-31504417

Asunto(s)

Interleucina-18; Interleucina-6; Anticuerpos Monoclonales; Anticuerpos Monoclonales Humanizados; Humanos; Interleucina-1beta

Palabras clave

Cardiovascular disease; Clinical trial; Inflammation; Interleukin-18; Interleukin-6

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Interleucina-6 / Interleucina-18 Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur Heart J Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google